u think 3% dividend makes for 15% loss of capital? stock has gone down from 114 to 96 despite strong economy and low fuel
$2.0 dividend/share with 10% per year growth till 2020...$18 billion backlog...85% fee based earnings .. Long term contracts .. $25 billion tax benefits over next 20 years due to asset depreciation ..
Negative is highly leveraged .. That's very normal for asset based companies like railroads , pipelines , utilities..anything that has hard physical assets
all short term money is out...that got in Jan-Feb when BIIB was at this level.
I feel BIIB will stagnate between 370-400 till next earnings...
...very shareholder friendly mgmt. $7 billion cash on books and increasing, no debt
goes to 135
any opinion.. i am already long cost avg. around 280
...got too much on downside.. actually this is good for long term health of stock..to shake out short term traders...as long as fundamentals intact..which i believe they are
We keep our 12-month target at $146 on a below peers 1.1X PE-to-growth ratio based on our 2015
EPS estimate. Q1 EPS of $1.07 vs. $0.83 is $0.03 ahead of our estimate. However, sales growth,
including 2% adverse forex impact, of 20.2% was below our 22% growth forecast. Revlimid sales
rose 17%, Abraxane rose 21%, and Pomalyst/Imnovie rose 46%, but Vidaza sales fell 3% on
generic competition. We remain encouraged by the growth of Revlimid and believe further label
expansion will drive continued demand and we see Abraxane sales reaching $1B this year.
highly overpriced, write to the Alexion investor relations....they paid premium for pipeline..but that's if and buts'
...or something we don't know/.
....time to load if it holds....